Ocular Therapeutix (OCUL) EBIT Margin (2014 - 2026)
Ocular Therapeutix's (OCUL) quarterly EBIT Margin came in at 865.46% in Q1 2026, down 26799.0% year-on-year from N/an in Q1 2025, and down 64.38% quarter-over-quarter from 526.49% in Q4 2025.
Ocular Therapeutix (OCUL) EBIT Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix's EBIT Margin history runs 13 years deep, the most recent figure standing at 865.46% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 26799.0% year-over-year to 865.46% in Q1 2026; TTM through Mar 2026 was 575.42%, a 23327.0% decrease from a year earlier, with the FY2025 full-year figure at 519.75%, down 25018.0% from the prior year.
- EBIT Margin retreated to 865.46% in Q1 2026 per OCUL's latest filing, from 526.49% in the prior quarter.
- Across five years, EBIT Margin topped out at 127.41% in Q3 2023 and bottomed at 865.46% in Q1 2026.
- The 5-year median for EBIT Margin is 214.0% (2024), against an average of 307.05%.
- Across the five-year window, EBIT Margin soared 14028 bps in 2022 and sank 38346 bps in 2025, its largest moves.
- Year by year, EBIT Margin stood at 137.56% in 2022, then grew by 2 bps to 135.46% in 2023, then sank by 119 bps to 296.08% in 2024, then sank by 78 bps to 526.49% in 2025, then sank by 64 bps to 865.46% in 2026.
- Per Business Quant, the three latest OCUL EBIT Margin figures stand at 865.46% (Q1 2026), 526.49% (Q4 2025), and 472.35% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ocular Therapeutix | 1.93 Bn | 1.93 Bn | 9.46 Mn | -865.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -865.46% |
| Dec 31, 2025 | -526.49% |
| Sep 30, 2025 | -472.35% |
| Jun 30, 2025 | -502.57% |
| Mar 31, 2025 | -597.47% |
| Dec 31, 2024 | -296.08% |
| Sep 30, 2024 | -298.20% |
| Jun 30, 2024 | -265.13% |
| Mar 31, 2024 | -214.00% |
| Dec 31, 2023 | -135.46% |
| Sep 30, 2023 | -127.41% |
| Jun 30, 2023 | -135.45% |
| Mar 31, 2023 | -168.60% |
| Dec 31, 2022 | -137.56% |
| Sep 30, 2022 | -180.06% |
| Jun 30, 2022 | -162.37% |
| Mar 31, 2022 | -135.23% |
| Dec 31, 2021 | -146.64% |
| Sep 30, 2021 | -160.69% |
| Jun 30, 2021 | -172.65% |